<DOC>
	<DOCNO>NCT00267917</DOCNO>
	<brief_summary>The objective trial compare total regional deposition aerosol lung oropharynx patient COPD know poor MDI inhalation technique follow inhalation Berodual ? deliver via Respimat ? inhaler Berodual ? deliver via HFA-metered dose inhal er achieve `` natural '' inhalation technique compare taught `` optimal '' technique .</brief_summary>
	<brief_title>Evaluation Respimat Inhaler vs. HFA MDI Using Berodual Patients With COPD With Poor MDI Technique .</brief_title>
	<detailed_description>This single dose , randomise , active-controlled , four period , open-label cross-over trial ad ult patient COPD demonstrate poor MDI technique . Berodual ? ( fenoterol hydrobromide 50 ? g + ipratropium bromide 20 ? g ) deliver via Respi mat ? inhaler two test day via MDI two test day . Test day instruction correct usage occur prior test day teach techniq ue , patient 's technique influence recent instruction . Each device thus first used instruction correct device use provide . On instruction test day device demonstrate patient allowed time practis e placebo device . The second time device use full instruction provide correct usage pat ients practise placebo either Respimat ? inhaler MDI judge competent . On two test day Respimat ? MDI inhaler fire investigator one second patient start inhale . Thus Test Days 1 2 patient use natural inhalation technique without receive instruction correct usage . On Test Days 3 4 patient use supervise optimal techn ique receive instruction correct usage investigator fire device . The primary analysis carry use Sign Test . This non-parametric analysis w hich assumption make shape distribution response Respimat ? inhaler MDI null hypothesis . Study Hypothesis : The null hypothesis poor technique effect Respimat ? MDI device . The alternative hypothesis poor technique differe nt effect Respimat ? inhaler MDI . This mean null hypothesis median difference Respimat ? inhaler MDI pair zero i.e . difference equally lik ely positive negative . Under alternative hypothesis median difference Respimat ? inhaler MDI pair zero i.e . frequency positive negative sign different . Comparison ( ) : Baseline comparability achieve use cross-over trial design every patient receive four treatment ensure test da baseline lung function within 15 % value obtain first est day , pre-dose FEV1 &lt; 65 % predict value patient abstain f rom inhale bronchodilator least 4 hour prior visit . Treatment equence fit term analysis variance model .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Inclusion criterion : COPD patient : FEV1 le equal 65 % pre FEV1 le equal 70 % FVC Exclusion criterion : Patients upper respiratory infection past 14 day prior creening visit ( visit 1 ) Patients unstable lifethreatening cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>